Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?

Fuyuhiko Motoi, Michiaki Unno

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Although upfront surgery has been the gold standard for pancreatic adenocarcinoma that is planned for resection, it should be compared with the alternative strategy of neoadjuvant therapy. Despite the many reports of the efficacy of neoadjuvant therapy, most of them were not comparative. Recently Prep-02/JSAP05 study clearly demonstrated the significant survival benefit of neoadjuvant chemotherapy over upfront surgery for pancreatic adenocarcinoma that is planned for resection. These findings opened a new chapter of neoadjuvant therapy. Ongoing trials are expected to confirm the evidence. This review summarizes the past, present, and future perspectives of neoadjuvant therapy and its optimization.

Original languageEnglish
Pages (from-to)100-108
Number of pages9
JournalAnnals of Gastroenterological Surgery
Volume4
Issue number2
DOIs
Publication statusPublished - 2020 Mar 1

Keywords

  • neoadjuvant chemotherapy
  • neoadjuvant therapy
  • pancreatic adenocarcinoma
  • resectable pancreatic cancer

ASJC Scopus subject areas

  • Gastroenterology
  • Surgery

Fingerprint Dive into the research topics of 'Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?'. Together they form a unique fingerprint.

  • Cite this